Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors

Pupo, 2022, AAV vectors: The Rubik’s cube of human gene therapy, Mol. Ther., 30, 3515, 10.1016/j.ymthe.2022.09.015 Flotte, 1996, A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease, Hum. Gene Ther., 7, 1145, 10.1089/hum.1996.7.9-1145 Russell, 2017, Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial, Lancet, 390, 849, 10.1016/S0140-6736(17)31868-8 Kuzmin, 2021, The clinical landscape for AAV gene therapies, Nat. Rev. Drug Discov., 20, 173, 10.1038/d41573-021-00017-7 Wang, 2019, Adeno-associated virus vector as a platform for gene therapy delivery, Nat. Rev. Drug Discov., 18, 358, 10.1038/s41573-019-0012-9 Vieira, 1982, The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers, Gene, 19, 259, 10.1016/0378-1119(82)90015-4 Spratt, 1986, Kanamycin-resistant vectors that are analogues of plasmids pUC8, pUC9, pEMBL8 and pEMBL9, Gene, 41, 337, 10.1016/0378-1119(86)90117-4 Ochiai, 1959, Studies on inheritance of drug resistance between Shigella strains and Escherichia coli strains, Nippon Iji Shimpo, 1861, 34 Davies, 1978, Plasmid-determined resistance to antimicrobial agents, Annu. Rev. Microbiol., 32, 469, 10.1146/annurev.mi.32.100178.002345 Helinski, 1976, R Factors: Infectious Multiple Drug Resistance. S. Falkow. Pion, London, 1975 (distributor, Academic Press, New York). xiv, 300 pp. + plates. $19.95. Pion Advanced Biochemistry Series, 4, Science, 192, 778, 10.1126/science.192.4241.778.a O’Brien, 1980, Dissemination of an antibiotic resistance plasmid in hospital patient flora, Antimicrob. Agents Chemother., 17, 537, 10.1128/AAC.17.4.537 Idsoe, 1968, Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock, Bull. World Health Organ., 38, 159 Guthe, 1958, Untoward penicillin reactions, Bull. World Health Organ., 19, 427 Chen, 2004, Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo, Gene Ther., 11, 856, 10.1038/sj.gt.3302231 Chadeuf, 2005, Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery, Mol. Ther., 12, 744, 10.1016/j.ymthe.2005.06.003 Sharma, 2013, Efficient sleeping beauty DNA transposition from DNA minicircles, Mol. Ther. Nucleic Acids, 2, e74, 10.1038/mtna.2013.1 Geguchadze, 2014, Proteomic profiling of salivary gland after nonviral gene transfer mediated by conventional plasmids and minicircles, Mol. Ther. Methods Clin. Dev., 1, 14007, 10.1038/mtm.2014.7 Holstein, 2018, Efficient non-viral gene delivery into human hematopoietic stem sells by minicircle sleeping beauty transposon vectors, Mol. Ther., 26, 1137, 10.1016/j.ymthe.2018.01.012 1993 1998 2001 2006 2016 2018 Chen, 2012, A survey of drug resistance bla genes originating from synthetic plasmid vectors in six Chinese rivers, Environ. Sci. Technol., 46, 13448, 10.1021/es302760s Schnödt, 2016, DNA minicircle technology improves purity of Adeno-associated viral vector preparations, Mol. Ther. Nucleic Acids, 5, e355, 10.1038/mtna.2016.60 Tai, 2018, Adeno-associated virus genome population sequencing achieves full vector genome resolution and reveals human-vector chimeras, Mol. Ther. Methods Clin. Dev., 9, 130, 10.1016/j.omtm.2018.02.002 Gray, 2017 Karbowniczek, 2017, DoggyboneTM DNA: an advanced platform for AAV production, Cell Gene Ther. Insights, 3, 731, 10.18609/cgti.2017.074 Kreiss, 1999, Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency, Nucleic Acids Res., 27, 3792, 10.1093/nar/27.19.3792 Mignon, 2015, Antibiotic-Free selection in biotherapeutics: now and forever, Pathogens, 4, 157, 10.3390/pathogens4020157 Li, 2009, Cellular immune response to cryptic epitopes during therapeutic gene transfer, Proc. Natl. Acad. Sci. USA, 106, 10770, 10.1073/pnas.0902269106 Monjezi, 2017, Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors, Leukemia, 31, 186, 10.1038/leu.2016.180 Danner, 2021, A homology independent sequence replacement strategy in human cells using a CRISPR nuclease, Open Biol., 11, 200283, 10.1098/rsob.200283 Florian, 2021, Gene engineered mesenchymal stem cells: greater transgene expression and efficacy with minicircle vs. plasmid DNA vectors in a mouse model of acute lung injury, Stem Cell Res. Ther., 12, 184, 10.1186/s13287-021-02245-5 Lu, 2012, The extragenic spacer length between the 5’ and 3’ ends of the transgene expression cassette affects transgene silencing from plasmid-based vectors, Mol. Ther., 20, 2111, 10.1038/mt.2012.65 Marie, 2010, pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells, J. Gene Med., 12, 323, 10.1002/jgm.1441 Luke, 2009, Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system, Vaccine, 27, 6454, 10.1016/j.vaccine.2009.06.017 Williams, 2014, Improving DNA vaccine performance through vector design, Curr. Gene Ther., 14, 170, 10.2174/156652321403140819122538 Carnes, 2010, Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields, J. Gene Med., 12, 818, 10.1002/jgm.1499 Hoogewoud, 2019, EYS606 for the Treatment of Non-Infectious Uveitis, Acta Ophthalmol., 97, 10.1111/j.1755-3768.2019.5326 Teixeira, 2020, A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors, Clin. Cancer Res., 26, 588, 10.1158/1078-0432.CCR-19-1614 Su, 2017, Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study, Hum. Vaccin. Immunother., 13, 2804, 10.1080/21645515.2017.1329070 Dutton, 2016, An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1, Hum. Vaccin. Immunother., 12, 3079, 10.1080/21645515.2016.1221872 Chandra, 2019, Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial, PLoS One, 14, e0226320, 10.1371/journal.pone.0226320 Suzuki, 2006, Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin, J. Virol., 80, 3293, 10.1128/JVI.80.7.3293-3300.2006 Darquet, 1997, A new DNA vehicle for nonviral gene delivery: supercoiled minicircle, Gene Ther., 4, 1341, 10.1038/sj.gt.3300540 Chen, 2003, Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo, Mol. Ther., 8, 495, 10.1016/S1525-0016(03)00168-0 Arévalo-Soliz, 2020, Improving therapeutic potential of non-viral minimized DNA vectors, Cell Gene Ther. Insights, 6, 1489, 10.18609/cgti.2020.163 Kay, 2010, A robust system for production of minicircle DNA vectors, Nat. Biotechnol., 28, 1287, 10.1038/nbt.1708 Williams, 2019 Lu, 2013, A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro, Mol. Ther., 21, 954, 10.1038/mt.2013.33 Lu, 2017, A 5’ noncoding exon containing engineered intron enhances transgene expression from recombinant AAV vectors in vivo, Hum. Gene Ther., 28, 125, 10.1089/hum.2016.140 Riu, 2007, Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo, Mol. Ther., 15, 1348, 10.1038/sj.mt.6300177 Carnes, 2006, Inducible Escherichia coli fermentation for increased plasmid DNA production, Biotechnol. Appl. Biochem., 45, 155, 10.1042/BA20050223 Abremski, 1986, Linking-number changes in the DNA substrate during Cre-mediated loxP site-specific recombination, J. Mol. Biol., 192, 17, 10.1016/0022-2836(86)90460-2 Nash, 1983, Site-specific recombination of bacteriophage lambda. The change in topological linking number associated with exchange of DNA strands, J. Mol. Biol., 170, 19, 10.1016/S0022-2836(83)80225-3 Zechiedrich, 1997, Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli, Genes Dev., 11, 2580, 10.1101/gad.11.19.2580 Weigl, 2006, Characterization of a topologically aberrant plasmid population from pilot-scale production of clinical-grade DNA, J. Biotechnol., 121, 1, 10.1016/j.jbiotec.2005.06.019 Boye, 2022, Reduction of plasmid vector backbone length enhances reporter gene expression, Bioelectrochemistry, 144, 107981, 10.1016/j.bioelechem.2021.107981 Boye, 2021, Cardioporation enhances myocardial gene expression in rat heart, Bioelectrochemistry, 142, 107892, 10.1016/j.bioelechem.2021.107892 Mitdank, 2022, Suicide nanoplasmids coding for ribosome-inactivating proteins, Eur. J. Pharm. Sci., 170, 106107, 10.1016/j.ejps.2021.106107 Chan, 2022, Delivery of non-viral naked DNA vectors to liver in small weaned pigs by hydrodynamic retrograde intrabiliary injection, Mol. Ther. Methods Clin. Dev., 24, 268, 10.1016/j.omtm.2022.01.006 Merting, 2022, Restoring FAS expression via lipid-encapsulated FAS DNA nanoparticle delivery is sufficient to suppress colon tumor growth in vivo, Cancers, 14, 361, 10.3390/cancers14020361 Vermeire, 2021, Improved potency and safety of DNA-encoded antibody therapeutics through plasmid backbone and expression cassette engineering, Hum. Gene Ther., 32, 1200, 10.1089/hum.2021.105 Luke, 2011, Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine, J. Virol., 85, 1370, 10.1128/JVI.01250-10 Dauphinee, 2022, EG-70, a novel non-viral gene therapy for local expression of innate and adaptive immune modulators for treatment of non-muscle invasive bladder cancer, Mol. Ther., 30, 155 Steinberg, 2023, Clinical results of a phase 1 study of intravesical EG-70 in patients with BCG-unresponsive NMIBC, J. Clin. Oncol., 41, 512, 10.1200/JCO.2023.41.6_suppl.512 Suschak, 2017, Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity, Hum. Vaccin. Immunother., 13, 2837, 10.1080/21645515.2017.1330236 Raturi, 2022, Immunogenicity of a SARS-CoV-2 DNA vaccine formulated with the fusion-associated small transmembrane protein proteolipid vehicle delivery system, SSRN J., 10.2139/ssrn.4241174 Borggren, 2015, Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans, Hum. Vaccin. Immunother., 11, 1983, 10.1080/21645515.2015.1011987 Suschak, 2020, Nanoplasmid vectors Co-expressing innate immune agonists enhance DNA vaccines for Venezuelan Equine Encephalitis virus and Ebola virus, Mol. Ther. Methods Clin. Dev., 17, 810, 10.1016/j.omtm.2020.04.009 Chowdhury, 2020, Experimental nanovaccine offers protection against repeat exposures to Trypanosoma cruzi through activation of Polyfunctional T cell response, Front. Immunol., 11, 3333, 10.3389/fimmu.2020.595039 Clauss, 2018, Efficient non-viral T-cell engineering by sleeping beauty minicircles diminishing DNA toxicity and miRNAs silencing the endogenous T-cell receptors, Hum. Gene Ther., 29, 569, 10.1089/hum.2017.136 Bozza, 2020, Novel non-integrating DNA Nano-S/MAR vectors restore gene function in isogenic patient-derived pancreatic tumor models, Mol. Ther. Methods Clin. Dev., 17, 957, 10.1016/j.omtm.2020.04.017 Roig-Merino, 2022, An episomal DNA vector platform for the persistent genetic modification of pluripotent stem cells and their differentiated progeny, Stem Cell Rep., 17, 143, 10.1016/j.stemcr.2021.11.011 Bozza, 2021, A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells, Sci. Adv., 7, eabf1333, 10.1126/sciadv.abf1333 Moretti, 2022, The past, present, and future of Non-Viral CAR T cells, Front. Immunol., 13, 867013, 10.3389/fimmu.2022.867013 Ostertag, 2020 Oh, 2022, High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA, J. Exp. Med., 219, e20211530, 10.1084/jem.20211530 Pomeroy, 2021, Non-Viral Engineering of CAR-NK and CAR-T cells using the Tc Buster Transposon SystemTM, bioRxiv Gurney, 2021, Tc buster transposon engineered CLL-1 CAR-NK cells efficiently target acute myeloid leukemia, Blood, 138, 1725, 10.1182/blood-2021-147244 Gurney, 2022, Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells, Cytotherapy, 24, 1087, 10.1016/j.jcyt.2022.07.008